Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by educational grants from
AbbVie and Jazz Pharmaceuticals
Description:
Acute myeloid leukemia (AML) is a cancer of the myeloid line of
blood cells, characterized by the rapid growth of abnormal white
blood cells that build up in the bone marrow and interfere with the
production of normal blood cells. AML is the most common acute
leukemia affecting adults, and its incidence increases with age.
Although AML is a relatively rare disease, accounting for roughly
1.2% of cancer deaths in the United States, its incidence is
expected to increase as the population ages. The American Cancer
Society estimates that there were approximately 19,940 new cases of
AML and 11,180 deaths from AML in the United States in 2021. The
five-year survival rate has not improved in older patient’s despite
of 40 years of research. Fortunately for patients with AML, many new
treatments have recently been approved for use. These options, which
are among the first new treatments in AML since 1990, have
drastically changed the treatment paradigm. With that change comes a
knowledge gap among physician medical directors, oncologists,
practicing physicians and nurses. For this reason, it is critical
that these HCPs are educated and updated on these emerging options
and strategies for their implementation into the treatment paradigm
which will ultimately improve patient outcomes in the AML patient
population.
Upon completion of this
activity, participants will be able to:
-
Examine the clinical and economic
burden of AML in terms of relative survival, mortality, drug
utilization, adverse event management, and hospitalizations
-
Compare and contrast the efficacy,
safety and mechanisms of action of current therapeutics in AML,
including newer targeted, cytotoxic, and antibody-based
strategies, in a range of patient populations
-
Evaluate evolving secondary AML
treatment strategies, including cytotoxic therapy options, and
show patient- and tumor-specific features can inform
decision-making in the context of outpatient care approaches
-
Discuss clinical and logistical
challenges related to secondary AML and potential advantages of
outpatient management for these patients
-
Assess the evolving role of BCL-2
inhibitors in patients with AML, including during maintenance
-
Review how patient- and
tumor-specific features can inform clinical and managed care
decision-making in secondary AML
-
Assess managed care considerations
to facilitate optimal use of novel combination options,
including cytotoxic therapy options, and optimal cost management
in AML, including secondary AML
|
Faculty: |
Nicholas Short, MD
Assistant Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center |
|
Disclosure:
|
(Relevant
Financial Relationships with Ineligible Companies in the
Last 24 Months):
Dr. Short has served as a consultant for Jazz
Pharmaceuticals, Pfizer, and Sanofi. He has served on
the speaker's bureau for Amgen, Astellas, Beigene,
Novartis, and Sanofi. He has received grant/research
support from Astellas, Stemline Therapeutics, Takeda
Oncology, and Xencor. His presentation has been reviewed
for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by
educational grants from
AbbVie and Jazz Pharmaceuticals
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |